Trinseo (NYSE: TSE), a global materials solutions provider and manufacturer of plastics, latex binders and synthetic rubber, will introduce its portfolio of thermoplastic elastomers (TPEs) for medical devices at two major industry shows: MD&M West in Anaheim, Calif. from February 5-7 at Booth 1986 and Pharmapack EU in Paris from February 6-7 at Booth D94. This portfolio of TPEs complements Trinseo’s traditional rigid plastics offering, making Trinseo a one-stop-shop for both hard and soft plastics.
Trinseo has supported the medical devices market for nearly three decades and is known for superior product quality, outstanding consistency, and a focus on customer compliancy requirements. The expanded portfolio enhances Trinseo’s offering with soft touch materials and overlays that are often needed with hard plastics.
TPEs can serve as a vinyl substitute. With their elastomeric composition, TPEs can allow better handling of medical devices and potentially increase performance, functionality, usability, and aesthetics, while helping to improve patient care and contribute to patient safety.
“We've brought together a very high quality portfolio of rigid plastics with TPEs that have been specifically formulated for the medical devices sector,” said Aldo Zanetti, business unit manager TPE Solutions - Medical & Packaging for Trinseo. “This move helps us meet the needs of medical customers, particularly as the industry addresses trends in health care that require medical devices and equipment that are more patient friendly and service provider friendly.”
Trinseo offers two styrenic block copolymers (TPSs) to the medical devices industry under the brands MEGOL™ and RAPLAN™. Materials are biocompatibility tested and available with full biocompatibility (MED) and limited testing approved for skin contact (SK), providing customers with the most economical material option, since not all medical devices require full biocompatibility.
Trinseo’s rigid plastics for medical devices include:
Trinseo supports medical devices customers with material solutions for Single and Multiple Use Devices, Equipment Housings, Drug Delivery Systems, and Medical Wearables. As the medical industry continues to evolve and bring life-enhancing devices to market, global medical device and pharmaceutical manufacturers rely on Trinseo to respond with materials developed to meet their needs. The company adheres to current Good Manufacturing Practices (cGMP) and holds an ISO 13485 certification.
Trinseo (NYSE: TSE), a specialty material solutions provider, partners with companies to bring ideas to life in an imaginative, smart, and sustainability-focused manner by combining its premier expertise, forward-looking innovations and best-in-class materials to unlock value for companies and consumers.
From design to manufacturing, Trinseo taps into decades of experience in diverse material solutions to address customers’ unique challenges in a wide range of industries, including consumer goods, mobility, building and construction, and medical.
Trinseo’s approximately 3,400 employees bring endless creativity to reimagining the possibilities with clients all over the world from the company’s locations in North America, Europe, and Asia Pacific. Trinseo reported net sales of approximately $4.8 billion in 2021. Discover more by visiting www.trinseo.com and connecting with Trinseo on LinkedIn, Twitter, Facebook and WeChat.
Cautionary Note on Forward-Looking Statements
This press release may contain forward-looking statements including, without limitation, statements concerning plans, objectives, goals, projections, strategies, future events or performance, and underlying assumptions and other statements, which are not statements of historical facts or guarantees or assurances of future performance. Forward-looking statements may be identified by the use of words like "expect," "anticipate," "intend," "forecast," "outlook," "will," "may," "might," "see," "tend," "assume," "potential," "likely," "target," "plan," "contemplate," "seek," "attempt," "should," "could," "would" or expressions of similar meaning. Forward-looking statements reflect management’s evaluation of information currently available and are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Factors that might cause future results to differ from those expressed by the forward-looking statements include, but are not limited to, our ability to successfully execute our transformation strategy and business strategy; our ability to integrate acquired businesses; global supply chain volatility, increased costs or disruption in the supply of raw materials or increased costs for transportation of our products; the nature of investment opportunities presented to the Company from time to time; and those factors discussed in our Annual Report on Form 10-K, under Part I, Item 1A —"Risk Factors" and elsewhere in our other reports, filings and furnishings made with the U.S. Securities and Exchange Commission from time to time. As a result of these or other factors, our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.
Trinseo Announces Quarterly Dividend of $0.01 Per Share
February 22, 2024
Trinseo Presents Specialty Solutions for the Medical Industry at MD&M West Expo in Anaheim
February 21, 2024
Trinseo Reports Fourth Quarter and Full-Year 2023 Financial Results; Provides First Quarter 2024 Outlook
February 12, 2024